IRAK4 Inhibition Makes a Splash in B-Cell Malignancies | Supplements and Featured Publications

October 17, 2024

Grzegorz S. Nowakowski, MD, discusses the potential implications of the TakeAim Lymphoma trial of emavusertib plus ibrutinib in patients with PCNSL.

September 11, 2024

Targeting IRAK4 with emavusertib could be a viable treatment option that offers needed blood-brain barrier penetration in PCNSL.

June 19, 2024

Emavusertib monotherapy was tolerable and produced responses in patients with FLT3-mutant relapsed/refractory acute myeloid leukemia.

June 12, 2024

Eric Winer, MD, discusses the safety and efficacy outcomes of the TakeAim Leukemia trial and future research with emavusertib in combination therapies.

March 12, 2024

The TakeAim Leukemia trial aims to add emavusertib to the treatment paradigm of acute myeloid leukemia and high-risk myelodysplastic syndrome.

March 01, 2024

Eric S. Winer, MD, discusses the mechanism of action of emavusertib and preliminary findings from the TakeAim Leukemia trial in acute myeloid leukemia.

February 26, 2024

Dr Mims discusses the utility of emavusertib in acute myeloid leukemia and myelodysplastic syndrome and the rationale for the TakeAim Leukemia trial.

February 12, 2024

Alice Mims, MD, discusses the toxicity profile and initial efficacy of emavusertib in heavily pretreated, FLT3-mutated relapsed/refractory AML.

January 10, 2024

Grzegorz S. Nowakowski, MD, discusses data from the phase 1/2 TakeAim Lymphoma trial of emavusertib plus ibrutinib in patients with hematologic malignancies.

December 08, 2023

Tapan M. Kadia, MD, discusses targeting the IRAK4 pathway in patients with acute myeloid leukemia and highlights the importance of utilizing targeted therapies in the treatment of patients with hematologic malignancies.

December 07, 2023

Eytan M. Stein, MD, discusses the ongoing development and investigation of therapies targeting splicing mutations in hematologic malignancies.